Ginkgo Bioworks Holdings Inc(DNA) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -5.44 | Insider Own | 24.12% | Shs Outstand | 52.3M | Perf Week | -3.56% |
| Market Cap | 0.46B | Forward P/E | - | EPS next Y | 20.55% | Insider Trans | -3.24% | Shs Float | 48.8M | Perf Month | -9.72% |
| Enterprise Value | 0.56B | PEG | - | EPS next Q | -1.01 | Inst Own | 58.7% | Short Float | 11.46% | Perf Quarter | -14.61% |
| Income | -0.32B | P/S | 4.08 | EPS this Y | 23.23% | Inst Trans | 8.15% | Short Ratio | 5.06 | Perf Half Y | -0.73% |
| Sales | 0.11B | P/B | 0.98 | EPS next 5Y | - | ROA | -26.55% | Short Interest | 5.60M | Perf YTD | -18.41% |
| Book/sh | 6.92 | P/C | 1.5 | EPS past 3/5Y | 51.73% -7.49% | ROE | -57.08% | 52W High | -61.43% ($17.58) | Perf Year | -34.11% |
| Cash/sh | 4.53 | P/FCF | - | Sales past 3/5Y | -29.11% 17.29% | ROIC | -38.25% | 52W Low | 26.26% ($5.37) | Perf 3Y | -91.85% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 7.05% | Gross Margin | 34.59% | Volatility(W/M) | 5.15% 6.3% | Perf 5Y | -98.27% |
| Dividend TTM | - | EV/Sales | 4.97 | Sales Y/Y TTM | -51.54% | Oper. Margin | -257.99% | ATR (14) | 0.46 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 4.57 | EPS Q/Q | -4.34% | Profit Margin | -281.87% | RSI (14) | 42.32 | Recom | 4.33 |
| Dividend Gr. 3/5Y | - | Current Ratio | 4.57 | Sales Q/Q | -59.37% | SMA20 | -3.49% ($7.03) | Beta | 1.9 | Target Price | $7 |
| Payout | - | Debt/Eq | 0.96 | Earnings | 2026/8/5 | SMA50 | -14.36% ($7.92) | Rel Volume | 0.61 | Prev Close | $6.79 |
| Employees | 485 | LT Debt/Eq | 0.96 | EPS/Sales Surpr. | 16.2% -16.19% | SMA200 | -18.28% ($8.3) | Avg Volume(3M) | 1.11M | Price | $6.78 |
| IPO | 2021/4/19 | Option/Short | Yes/Yes | Trades | 5731 | Volume | 679,181 | Change | -0.15% |
Company
DNA is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
🧬 Ginkgo Bioworks (ticker: DNA) is a U.S. synthetic biology company that operates a cell engineering platform. It programs microorganisms and cells as if designing software, supporting customers across a range of industries—including pharmaceuticals, food, agriculture, and chemicals—in developing new materials through its automated foundry, and it also operates a separate biosecurity business.
Over the past 1 year, on the lower side
61% below its 1-year high.
DNA has weak earning power
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +23.2% this year.
Tap to view numbers
The price looks about right
Trading at - times earnings.
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Sell.
Tap to view numbers
Holding long would have lost money
Would have changed by -91.8% if bought 5 years ago.
Tap to view numbers
Dividends are hard to expect
This stock does not pay dividends
Ownership is about average
Institutions hold 58.7%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
THNQ 0.01%
WDNA 0.01%
IDNA 0.00%
ISMD 0.00%
KOMP 0.00%It ranks #4 in the industry
Based on market cap of $457M.
DNA $457M PER -
VRTX $130B PER 29.9
REGN $82B PER 19.6
ARGX $62B PER 37.5
FAQ
What kind of company is DNA?
DNA belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of DNA?
The market cap of DNA is approximately $457M, ranking 3,299 within its sector.
What is the 52-week high and low for DNA?
DNA has recorded a 52-week high of $17.58 and a low of $5.37.
